Compare Gilead Sciences, Inc. (GILD) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NIO Inc. — how do they compare? Gilead Sciences, Inc. trades at $149.66 (market cap $182.40B), while NIO Inc. trades at $3.61 (market cap $8.62B). The key difference: Gilead Sciences, Inc. is far larger — about 21.2× NIO Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and NIO Inc. for 81 Days on average.
| GILD | NIO | |
|---|---|---|
Market Cap | $182.40B | $8.62B |
Volume | 4,469,821 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $7.46 |
52-Week Low | $116.74 | $3.37 |
Typical Hold Time | 111 Days | 81 Days |
Enterprise Value | $205.46B | $6.52B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
NIO trades at $3.54, up 1.72% today but near a 52-week low, with a bearish technical signal. Revenue grew to $87.49B in 2025, yet net losses persist at -$15.57B, though margins improved. Recent Q3 2026 deliveries rose 25.4%, and a strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38B.
The outlook hinges on scaling profitability amid a brutal EV price war. Analysts see 76% upside to a $6.23 target, but high debt and cash burn pose risks. Sentiment is mixed, with news highlighting growth potential against competitive and macroeconomic headwinds in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
